当地时间 6 月 29 日,默沙东在ClinicalTrials.gov 官网上登记了一项评估每月一次口服 MK-8527 用于 HIV-1 暴露前预防有效性和安全性的 III 期临床试验(MK-8527-011)。来源:ClinicalTrials.gov 官网这是一项随机、双盲、活性药物对照的 III 期临床研究,计划入组4390 名受试者,纳入标准如下图所示。来源:...
Source Link当地时间 6 月 29 日,默沙东在ClinicalTrials.gov 官网上登记了一项评估每月一次口服 MK-8527 用于 HIV-1 暴露前预防有效性和安全性的 III 期临床试验(MK-8527-011)。来源:ClinicalTrials.gov 官网这是一项随机、双盲、活性药物对照的 III 期临床研究,计划入组4390 名受试者,纳入标准如下图所示。来源:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.